ArticleCommunications medicine2025
In-situ dual-lighting system for HER2 nucleic acid and protein co-localization through simultaneous visual signal amplification in single pathological sections.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comprehensive clinical outcomes of TiRobot-assisted minimally invasive surgery for pelvic fractures: a meta-analysis.Journal of robotic surgery · 2026Pooled it
- Applications and development of in situ nucleic acid visualization techniques.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pathological state of human epidermal growth factor receptor-2 (HER2) determines the treatment strategies. Immunohistochemistry (IHC) and in situ hybridization (ISH) are the only two recognized diagnostic methods for HER2-positive (HER2 + ). IHC, although widely used, has limited reliability and often requires further confirmation by ISH for IHC ≤ 2 + . Furthermore, studies have demonstrated that HER2-low patients may still benefit from HER2-targeted therapy, highlighting the need for accurate and sensitive detection methods.
methodsIn this study, we designed the molecular beacon (MB) for HER2 amplification detection. Subsequently, the in-situ dual-lighting system (ISDLS) was established by combining MB-based loop-mediated isothermal amplification (LAMP) and tyramide signal amplification (TSA)-based IHC for HER2 in-situ nucleic acid and protein detection in a single sample, and was verified in both cell line slides and human tumor sections. To better elucidate the significance of our study, we compared the test results with clinical reports.
resultsHere, we show that, in a single sample, satisfactory nucleic acid and protein signals are obtained, especially in human tumor sections within one day. The detection rate for clinical IHC ≥ 1+ and fluorescence in situ hybridization amplification (FISH + ) sections reaches 100%, and the detection rate of clinical FISH- sections reaches 77.8%.
conclusionsISDLS enables the spatial in-situ distribution of amplified nucleic acid and protein signals in one section, providing a basis for multidimensional analysis of diseases. ISDLS is also expected to improve the speed, sensitivity, and accuracy of detection compared to other methods.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.